Cargando…

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease: Results of the HOT‐TOPIC trial after 1‐year follow‐up

BACKGROUND: Previously published short‐term results (week 16) of this trial showed a significant improvement in clinical, radiologic and biochemical outcomes in Crohn's disease patients with therapy‐refractory perianal fistulas after treatment with hyperbaric oxygen therapy. OBJECTIVE: To asses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lansdorp, Corine A., Buskens, Christianne J., Gecse, Krisztina B., Löwenberg, Mark, Stoker, Jaap, Bemelman, Willem A., D’Haens, Geert R. A. M., van Hulst, Rob A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911540/ https://www.ncbi.nlm.nih.gov/pubmed/35146959 http://dx.doi.org/10.1002/ueg2.12189

Ejemplares similares

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease
por: Lansdorp, Corine A., et al.
Publicado: (2020)

Wound healing of metastatic perineal Crohn’s disease using hyperbaric oxygen therapy: A case series
por: Lansdorp, Corine A, et al.
Publicado: (2020)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

Hyperbaric oxygen therapy: More hope than hype for future treatment of perianal fistulizing Crohn's disease?
por: Armuzzi, Alessandro, et al.
Publicado: (2022)

Hyperbaric oxygen therapy for the treatment of rectovaginal fistulas in patients with Crohn’s disease: results of the HOT-REVA pilot study
por: Lansdorp, C A, et al.
Publicado: (2021)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

Diagnostic accuracy of faecal calprotectin in patients with active perianal fistulas
por: Stevens, Toer W, et al.
Publicado: (2019)

Developing a core outcome set for fistulising perianal Crohn’s disease
por: Sahnan, Kapil, et al.
Publicado: (2019)

Perianal fistulizing Crohn's disease and overall risk of cancer: No red flag
por: McLellan, Paul, et al.
Publicado: (2023)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Next-Generation Therapeutics for IBD
por: Löwenberg, Mark, et al.
Publicado: (2015)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Malignancy rates in Crohn's disease patients with perianal fistula: A German retrospective cohort study
por: Podmore, Bélène, et al.
Publicado: (2023)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
por: Hart, Ailsa, et al.
Publicado: (2022)

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial
por: Panés, Julian, et al.
Publicado: (2023)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
por: Hébuterne, Xavier, et al.
Publicado: (2013)

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
por: Panaccione, Remo, et al.
Publicado: (2020)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale
por: Adegbola, Samuel O, et al.
Publicado: (2021)

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
por: Sandborn, William J, et al.
Publicado: (2018)

Fibrosis and MAGNIFI-CD Activity Index at Magnetic Resonance Imaging to Predict Treatment Outcome in Perianal Fistulizing Crohn’s Disease Patients
por: van Rijn, Kyra L, et al.
Publicado: (2021)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Assessing Disease Activity in Pediatric Crohn’s Disease Using Ultrasound: The Pediatric Crohn Disease Intestinal Ultrasound Score
por: van Wassenaer, Elsa A., et al.
Publicado: (2023)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
por: Sandborn, W. J., et al.
Publicado: (2015)

Volume assessment magnetic resonance imaging technique for monitoring perianal Crohn’s fistulas
por: Lung, Phillip F. C., et al.
Publicado: (2018)

Treat‐to‐target and sequencing therapies in Crohn's disease
por: Garcia, Nicole M., et al.
Publicado: (2022)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
por: Koelink, Pim J, et al.
Publicado: (2020)

A microbial signature for Crohn's disease
por: Pascal, Victoria, et al.
Publicado: (2017)

Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy alone for Crohn's perianal fistulas (PISA-II): long-term outcomes of an international, multicentre patient preference, randomised controlled trial
por: Meima - van Praag, Elise M., et al.
Publicado: (2023)

A novel unconventional T cell population enriched in Crohn’s disease
por: Rosati, Elisa, et al.
Publicado: (2022)

Bacterial protein signals are associated with Crohn’s disease
por: Juste, Catherine, et al.
Publicado: (2014)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Inability to walk: a rare presentation of Crohn’s disease
por: Hoekstra, Elmer, et al.
Publicado: (2020)

Variables associated with progression of moderate-to-severe Crohn’s disease
por: Sacramento, Carolina da Silva Beda, et al.
Publicado: (2022)

Factors affecting outcomes in Crohn's disease over 15 years
por: Cosnes, Jacques, et al.
Publicado: (2012)

Creeping fat formation and interaction with intestinal disease in Crohn's disease
por: Yin, Yi, et al.
Publicado: (2022)

Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial
por: Cozijnsen, M A, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1d4ani8b5h00gs1rr8h14s145n